Risks Associated With Transcatheter PDA Occlusions in Lower Weight Infants
Transcatheter patent ductus arteriosus (PDA) occlusion is one of the safest interventional cardiac procedures among adults and children. However, major adverse events are five to 10 times greater among infants who weigh less than six kilograms, according to a study published August 16 in JACC: Cardiovascular Interventions.
Using ACC’s IMPACT Registry, Carl H. Backes, MD, et al., identified 747 infants weighing less than six kilograms who underwent transcatheter PDA occlusion between January 2011 and March 2015. Across 73 hospitals, the procedural success rate was 94.3 percent, and 96 percent of cases required less than two hours in the catheterization suite.
Regarding the study population, researchers examined differences by grouping the infants into three weight categories: extremely low weight (ELW, <2 kilograms), very low weight (VL, 2-<4 kilograms) and low weight (LW, 4-<6 kilograms). A third of the infants studied were born at <30 weeks of gestation. At catheterization, the median age was 4.3 months and most were LW (4.6 kilograms). Additionally, more than half of procedures were performed on females and Caucasians. Less than half of the infants were hospitalized before the procedure and more than half were on diuretic treatment. Most infants had a Type A (37 percent) or Type C (42 percent) PDA.
While the majority of attempted PDA closures were successful, approximately 13 percent of the infants experienced major adverse events (MAEs). “In the present cohort of infants <6 kg, procedural success rates for transcatheter PDA closure are similar to those in more mature counterparts, but rates of MAE were 5-10 fold greater,” note the study authors.
Most common MAEs included acute arterial injury (3.5 percent) and device embolization (2.4 percent). ELW infants (10.5 percent) had a higher risk of embolization than VLW or LW infants (1.6 percent and 2.5 percent, respectively; p = 0.050). Other noted MAEs included arrhythmia requiring intervention, unplanned cardiac surgery and a major bleeding event (less than 2 percent each). Infants who experienced an MAE were more likely to stay at the hospital a week longer than those who did not (13 vs. 20 days, p = 0.01). Additionally, risk of MAEs (odds ratio [OR], 3.4; 95 percent confidence interval [CI], 1.5-7.9) and composite failure (OR, 3.1; 95 percent CI, 1.4-6.9) was higher among younger patients (<30 days).
While the study proves to be an “important first step in understanding the risk profile of transcatheter PDA occlusion in this subgroup of infants,” the authors note that “conclusions on the optimal treatment among lower weight infants with a persistent ductus remain unanswered.”
“Conservative treatment may reduce unnecessary interventions in many infants, but the question remains as to what to do if the PDA fails to close following a period of conservative treatment,” they continue.
“Well-designed comparative trials (transcatheter occlusion, surgical ligation, conservative treatment) that use clearly defined inclusion criteria and treatment thresholds, standardized protocols for AE surveillance, and long-term follow-up, are needed.”
Clinical Topics: Arrhythmias and Clinical EP, Congenital Heart Disease and Pediatric Cardiology, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Congenital Heart Disease, CHD and Pediatrics and Arrhythmias, CHD and Pediatrics and Prevention, CHD and Pediatrics and Quality Improvement, Statins
Keywords: Ductus Arteriosus, Patent, Odds Ratio, Ligation, Confidence Intervals, Research Personnel, Follow-Up Studies, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Etoposide, Mitoxantrone, Catheterization, Arrhythmias, Cardiac, Registries, Diuretics
< Back to Listings